A phase III, pivotal study of recombinant human Alkaline Phosphatase (recAP) in patients with sepsis-associated acute kidney injury (SA-AKI)
Phase of Trial: Phase III
Latest Information Update: 16 Jul 2019
Price : $35 *
At a glance
- Drugs Alkaline phosphatase (Primary)
- Indications Acute kidney injury
- Focus Registrational; Therapeutic Use
- Sponsors AM-Pharma
- 16 Jul 2019 According to an AM-Pharma media release, the company has raised funds from the European syndicate of new and existing investors which will be used to carry out this multi-national pivotal Phase III trial of recAP. The company looks forward to work with the expanded investor syndicate to initiate this trial.
- 16 Jul 2019 According to an AM-Pharma media release, the company plans to submit market authorization applications following the successful completion of this upcoming pivotal study.
- 31 Oct 2018 New trial record